AN2 Therapeutics, Inc.

NASDAQ:ANTX

Biotechnology

Healthcare
$4.95 +0.82%

+$0.04 today

Market cap
$187.82M
Beta
-0.98
P/E (TTM)
-4.9
EPS (TTM)
-$1.01
52W Low $1.00High $6.91

Volume 0.97M

Average 0.29M

ANTX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

AN2 Therapeutics, Inc.NASDAQ: ANTX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 34.06M shares rose 13.3% year over year, ahead of the +4.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 12.7% from the prior quarter. Over 3 fiscal years it compounded at +25.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +13.3% holds above the trailing-twelve-month pace of +4.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
34.06M+12.7% QoQ
Last fiscal yearDec 2025
30.22M+1.3% YoY
LTMMar 2026
31.18M+4.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.3%——
1 year+1.3%——
3-year CAGR+25.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
30.22M USD
Year-over-year change
+1.3%
4-year CAGR
+12.7%

Weighted Avg Shares vs competitors

How ANTX compares with its peers on the latest reported figures

  • ANTX's LTM Mar 2026 weighted avg shares of 31.18M shares is the 3rd highest of the 6 companies compared; the peer median is 22.38M shares.
  • Its year-over-year change of +4.3% is the lowest of 6, against a peer median of +57.7%.
  • Over three fiscal years its annual growth of +25.4% compares with a peer median of +56.8%.
ANTX Competitors Peer median
Weighted Avg Shares for ANTX and competitors
Company Period LTM YoY 3-year CAGR
IBIOiBio, Inc.LTM Jun 202693.94M +753.1%+453.9%
SABSSAB Biotherapeutics, Inc.LTM Jun 202640.82M +340.0%+64.3%
ANTXAN2 Therapeutics, Inc.LTM Mar 202631.18M +4.3%+25.4%
BOLDBoundless Bio, Inc.LTM Mar 202622.38M +7.1%+0.2%
QTTBQ32 Bio Inc.LTM Mar 202612.77M +5.5%+56.8%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 202610.07M +57.7%+46.1%
Peer median (excluding ANTX) 22.38M+57.7%+56.8%

Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue077K000
Gross Profit0(77K)000
Gross Margin—————
Research & Development16.91M29.51M54.87M40.49M24.77M
Selling, General & Admin4.67M12.75M14.76M14.07M13.34M
Operating Expenses21.57M42.19M69.64M54.55M38.11M
Depreciation & Amortization077K69.64M54.55M0
EBITDA(21.54M)(40.88M)4.9M3.23M(35.17M)
EBITDA Margin—————
Operating Income(21.57M)(42.26M)(69.64M)(54.55M)(38.11M)
Operating Margin—————
Interest Income69K1.35M4.86M5.47M2.93M
Interest Expense0514K000
Other Income / Expenses31K1.31M4.9M3.23M2.94M
Income Before Tax(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Net Margin—————
EPS (Basic)(1.50)(2.79)(2.74)(1.72)(1.16)
EPS (Diluted)(1.50)(2.79)(2.74)(1.72)(1.16)
Weighted Avg Shares18.74M15.34M23.6M29.83M30.22M
Weighted Avg Shares (Diluted)18.74M15.34M23.6M29.83M30.22M

AN2 Therapeutics, Inc.

NASDAQ:ANTX

Intrinsic Alpha fair value

Locked

Current Price

$4.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.